Factory Supply Acetylacetone - 2′,3′-Di-O-acetyl-5′-deoxy-5-fluorocytidine CAS 161599-46-8 Purity ≥99.0% Capecitabine Intermediate – Ruifu

Manufacturer with High Purity and Stable Quality
Commercial Supply Capecitabine (CAS: 154361-50-9) Related Intermediates:
5-Fluorocytosine CAS: 2022-85-7
2′,3′-Di-O-acetyl-5′-deoxy-5-fluorocytidine CAS: 161599-46-8
1,2,3-Tri-O-acetyl-5-deoxy-β-D-ribofuranose CAS: 62211-93-2
Capecitabine CAS: 154361-50-9

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer’s requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Manufacturer with High Purity and Stable Quality
Commercial Supply Capecitabine (CAS: 154361-50-9) Related Intermediates:
5-Fluorocytosine CAS: 2022-85-7
2′,3′-Di-O-acetyl-5′-deoxy-5-fluorocytidine CAS: 161599-46-8
1,2,3-Tri-O-acetyl-5-deoxy-β-D-ribofuranose CAS: 62211-93-2
Capecitabine CAS: 154361-50-9

Capecitabine is a new oral fluoropyrimidine carbamate for patients with advanced neoplastic disease, approved as Xeloda for the treatment of refractory metastatic breast cancer after failure on Paclitaxel and an anthracycline-based chemotherapy regimen ; it is a prodrug of doxifluridine (5-fluorouracil ; 5-FU) activated by a cascade of 3 enzymes concentrated in human liver and cancer tissue, resulting in the selective release of 5-FU at the tumor site and offering a prolonged tumour exposure to 5-FU. Oral Capecitabine passes intact through the intestinal mucosa, is converted first by carboxylesterase to 5′-deoxy-5- fluorocytidine in the liver, then by cytidine deaminase to 5′-deoxy-5-fluorouridine in the liver and tumour tissues and finally by thymidine phosphorylase to 5-FU in tumors. Therefore, Xeloda is much safer and more effective than 5-FU (for example, in the HCT116 human colon cancer and the MX-1 breast cancer xenograft .models).